There has been an extensive search for biomarkers (BMs) that could guide therapy beyond PD‐L1 expression and results have revealed that high tumor mutation burden (TMB), as well as a T‐cell inflamed signature, may further stratify NSCLC patients into responders vs. nonresponders to ICIs [13]. The gene discussed is CD274; the disease is neoplasm.